# CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis

> **NCT03168256** · PHASE3 · COMPLETED · sponsor: **Can-Fite BioPharma** · enrollment: 528 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** CF101 2mg
- **DRUG:** CF101 3mg
- **DRUG:** Apremilast 30mg
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03168256
- **Lead sponsor:** Can-Fite BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-15
- **Primary completion:** 2022-01-06
- **Final completion:** 2022-04-27
- **Target enrollment:** 528 (ACTUAL)
- **Last updated:** 2022-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03168256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03168256, "CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03168256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*